Items where authors include "Plummer, R."

Article

Kohlrausch, E.C., Ghaderzadeh, S., Aliev, G.N. et al. (14 more authors) (2025) One‐Size‐Fits‐All: A Universal Binding Site for Single‐Layer Metal Cluster Self‐Assembly. Advanced Science. e08034. ISSN 2198-3844

Sacco, J.J., Jackson, R., Corrie, P. et al. (18 more authors) (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202. 114009. ISSN 0959-8049

Kristeleit, R. orcid.org/0000-0003-3825-1326, Plummer, R., Jones, R. et al. (11 more authors) (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129. pp. 38-45. ISSN 0007-0920

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Yap, T.A., Plummer, R., Azad, N.S. et al. (1 more author) (2019) The DNA damaging revolution : PARP inhibitors and beyond. American Society of Clinical Oncology Educational Book (39). pp. 185-195. ISSN 1548-8748

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931

Conference or Workshop Item

Lahu, G., Banerji, U., Tap, W.C. et al. (15 more authors) (2025) Abstract CT151: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates. In: AACR Annual Meeting 2025, 25-30 Apr 2025, Chicago, Illinois.

Proceedings Paper

Banerji, U., Cook, N., Anthoney, A. et al. (11 more authors) (2024) Abstract CT188: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. In: Cancer Research. AACR Annual Meeting 2024, 05-10 Apr 2024, San Diego, USA. American Association for Cancer Research , ct188-ct188.